Status In progress
Process TAG
ID number 3754

Project Team

Project lead Jo Ekeledo

Email enquiries

Evidence Review Group / Assessment Group Kleijnen Systematic Reviews Ltd


Companies sponsors Dova Pharmaceuticals (avatrombopag)
  Shionogi Inc (lusutrombopag)
Others Department of Health and Social Care
  NHS England
  Welsh Government
Patient carer groups British Liver Trust
Professional groups British Association for the Study of the Liver
  British Society of Gastroenterology
  British Society for Haematology
  Royal College of Pathologists
  Royal College of Physicians
  UK Clinical Pharmacy Association


Associated public health groups None
Comparator companies None
General commentators British National Formulary
  Department of Health, Social Services and Public Safety for Northern Ireland
  Healthcare Improvement Scotland
  Scottish Medicines Consortium
  Welsh Health Specialised Services Committee
Relevant research groups Foundation for Liver Research


Key events during the development of the guidance:

Date Update
04 March 2020 - 18 March 2020 Final appraisal document: 1
04 February 2020 The Department for Health and Social Care has asked NICE to conduct an appraisal of avatrombopag and lusutrombopag for treating thrombocytopenia in people with chronic liver disease needing an elective procedure [ID1520] Please note Avatrombopag was split from Lusutrombopag because a list price in the UK had not yet been agreed. Lusutrombopag has now been recommended and guidance has been issued TA617. Avatrombopag will now continue as a separate appraisal.
03 February 2020 In progress, Topic referred March 20 2006

For further information on how we develop guidance, please see our page about NICE technology appraisal guidance